Genmab to Participate in a Fireside Chat at the Goldman Sachs 45th Annual Global Healthcare ConferenceGlobeNewsWire • 06/05/24
Investigational Tisotumab Vedotin Phase 2 Data Demonstrates Encouraging Antitumor Activity in Patients with Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)GlobeNewsWire • 06/03/24
Preliminary Analysis of Data Evaluating Investigational Epcoritamab (DuoBody® CD3xCD20) Combination Demonstrates 95% Overall Response Rate in Patients with Previously Untreated Follicular LymphomaGlobeNewsWire • 06/02/24
Investigational Acasunlimab (DuoBody® -PD-L1x4-1BB) in Combination with Pembrolizumab Demonstrates Meaningful Clinical Activity in Phase 2 Trial in Patients with Previously Treated Metastatic Non-small Cell Lung Cancer (mNSCLC)Business Wire • 06/01/24
Genmab to Showcase Data in Various Patient Populations to be Presented at the American Society of Clinical Oncology (ASCO) Annual MeetingBusiness Wire • 05/23/24
Genmab to Present New and Updated Results From Multiple Clinical Trials Evaluating Epcoritamab Across Various B-Cell Malignancies at the 2024 European Hematology Association (EHA) CongressBusiness Wire • 05/14/24
TIVDAK® (tisotumab vedotin-tftv) Receives U.S. FDA Approval to Treat Recurrent or Metastatic Cervical CancerBusiness Wire • 04/29/24
FDA Grants Full Approval for TIVDAK® to Treat Recurrent or Metastatic Cervical CancerBusiness Wire • 04/29/24
Genmab Announces Net Sales of DARZALEX® (daratumumab) for First Quarter of 2024GlobeNewsWire • 04/16/24
Genmab Slumps On Its $1.8 Billion Takeover Of Cancer Specialist ProfoundBioInvestors Business Daily • 04/03/24
Genmab to Broaden and Strengthen Oncology Portfolio with Acquisition of ProfoundBioBusiness Wire • 04/03/24
Constitution of the Board of Directors in Genmab A/S, Grant of Restricted Stock Units to Board Members and Employees and Grant of Warrants to Employees in GenmabGlobeNewsWire • 03/13/24